Chronic Diseases
Chronic diseases are long-lasting (or slowly emerging) conditions, often requiring ongoing medical attention and featuring periods of remission and relapse. A rapid rise in chronic diseases has imposed great health, social, and economic costs, as well as contributing to an overburdened healthcare system.
Altering the trajectory of HIV in Europe
22 May 2025
Despite substantial medical advancements that have transformed HIV into a manageable chronic condition for individuals, the epidemic remains a pressing public health concern in Europe.
Understanding the Full Value of Long-Acting Therapies: less is more?
7 May 2025
Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.
Advancing Rare Disease Care: Challenges and Key Issues
28 February 2025
Today marks Rare Disease Day 2025. This time last year we published an Article entitled “ Why do we care about rare?”, summarising the origins of…
OHE’s submission for the DHSC’s next 10 years of planning
9 December 2024
This Insight summarises the recommendations OHE submitted towards the Department of Health & Social Care’s consultation on the next 10 years of planning for the NHS.
A Spotlight on Haemophilia Therapies
3 October 2024
Pharmaceutical innovation is a key driver of improvements in health outcomes, quality of life and productivity for people with acute and chronic conditions.
Inequalities in Dementia: Unveiling the Evidence and Forging a Path Towards Greater Understanding
26 June 2024
Our literature review suggests that there are more than 100 inequalities impacting on people living with dementia and their carers across multiple characteristics, circumstances, and in various parts of the health and care system. However, the current low availability and quality of data is a major barrier to accurately measuring these inequalities. With the expectation that 1 in 2 people will be affected by dementia during their lifetime, there is a pressing need for further research to inform future policy, research, and service interventions.
The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society
18 July 2023
The report highlights the burden of Hidradenitis Suppurativa (HS) on patients, the NHS and society and makes recommendations to improve life for people living with HS and lessen the burden on the NHS and wider society. The foreword has been provided by Angela Gibbons, patient and HS advocate.
This project has been organised and funded by Novartis Pharmaceuticals UK Ltd, with support from M+F Health. The report is informed by input from experts working in HS, including leading clinicians.
After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
1 November 2021
Around 10% of people in the United Kingdom (UK) have chronic kidney disease (CKD) according to Kidney Care UK. While CKD can be managed through diet and…